News & Videos - CALCIMEDICA INC. - English

You are currently viewing all stock exchange news of the financial instrument CALCIMEDICA INC. regarding all markets in English.

> News GlobeNewsWire published a news.

CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates • • GlobeNewsWire • Stocks

International expansion of CARPO, a Phase 2b clinical trial of Auxora in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS), in India Expansion of team with key leadership appointments in regulatory and clinical development Filing of an investigational new drug (IND) application for Auxora in acute kidney injury (AKI) expected by year-end 2023 LA JOLLA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a...

Thank you Chart

> News GlobeNewsWire published a news.

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP) • • GlobeNewsWire • Stocks

CARPO top-line data expected in 1H2024 CARPO enrolling in over 30 sites in the US and India LA JOLLA, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (NASDAQ: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that its ongoing CARPO trial, a Phase 2b trial evaluating Auxora™ for the...

Thank you Chart

> News GlobeNewsWire published a news.

CalciMedica Announces Relisting on Nasdaq • • GlobeNewsWire • Stocks

LA JOLLA, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced that The Nasdaq Stock Market LLC has approved CalciMedica’s application for the relisting of the Company’s common stock on the Nasdaq Capital Market. The Company’s common stock is expected to commence trading on the Nasdaq Capital...

Thank you Chart

> News GlobeNewsWire published a news.

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP) • • GlobeNewsWire • Stocks

Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP Data show that inhibiting Orai1-mediated store-operated Ca 2+ entry (SOCE) with a selective CRAC channel inhibitor prevented the progression of RAP and early CP into established CP LA JOLLA, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing...

Thank you Chart

> News GlobeNewsWire published a news.

CalciMedica Expands Executive Team with New Appointments • • GlobeNewsWire • Stocks

LA JOLLA, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the appointments of Raven Jaeger, M.S., as Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, as Senior Vice President of Clinical Development. Both Mrs. Jaeger and Dr. Cunningham bring extensive expertise to their positions on the...

Thank you Chart

> News GlobeNewsWire published a news.

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates • • GlobeNewsWire • Stocks

LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended March 31, 2023. “We ended our first quarter as a public company in a strong position, with a cash runway that will last into the second half of 2024,” said Rachel Leheny, Ph.D., Chief...

Thank you Chart